ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Shionogi & Co., Ltd.

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue333,371M3,066.16M
Gross Profit270,042M2,483.69M
Operating income130,534M1,200.58M
Income before tax158,516M1,457.94M
Net income122,193M1,123.86M
EBITDA144,649M1,330.40M
Diluted EPS395.283.63
Dividends Per Share1030.94
Total Assets871,526M8,073.04M
Total liabilities106,610M987.54M
Total equity764,560M7,082.21M
Operating cash flow131,940M1,213.51M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 309,973M 338,890M 344,667M 367,960M 333,371M
Gross Profit 235,215M 261,113M 270,756M 305,713M 270,042M
Operating income 91,406M 108,179M 115,219M 168,370M 130,534M
Income before tax 97,452M 122,695M 137,378M 174,043M 158,516M
Net income 66,687M 83,878M 108,866M 137,190M 122,193M
EBITDA 107,275M 124,519M 134,226M 187,074M 144,649M
Diluted EPS 201.70 255.87 337.42 434.70 395.28
Dividends Per Share 62 72 82 94 103
Total Assets 639,638M 670,271M 711,463M 938,540M 871,526M
Total liabilities 125,761M 144,058M 106,619M 125,125M 106,610M
Total equity 509,792M 522,737M 601,374M 808,774M 764,560M
Operating cash flow 102,290M 111,903M 129,790M 165,000M 131,940M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,581.29M 3,129.53M 3,109.80M 3,318.10M 3,066.16M
Gross Profit 1,958.74M 2,411.29M 2,442.93M 2,756.78M 2,483.69M
Operating income 761.18M 998.99M 1,039.57M 1,518.28M 1,200.58M
Income before tax 811.52M 1,133.04M 1,239.51M 1,569.44M 1,457.94M
Net income 555.33M 774.58M 982.25M 1,237.11M 1,123.86M
EBITDA 893.33M 1,149.89M 1,211.07M 1,686.95M 1,330.40M
Diluted EPS 1.67 2.36 3.04 3.92 3.63
Dividends Per Share 0.51 0.66 0.73 0.84 0.94
Total Assets 5,690.98M 6,015.17M 6,689.82M 8,479.37M 8,073.04M
Total liabilities 1,118.91M 1,292.81M 1,002.52M 1,130.46M 987.54M
Total equity 4,535.71M 4,691.16M 5,654.66M 7,306.98M 7,082.21M
Operating cash flow 851.81M 1,033.38M 1,171.04M 1,487.89M 1,213.51M

Valuation Measures

Mar 2020
PER13.43
ROA13.50%
ROE15.53%
Operating margin39.15%
Profit margin36.65%

Key executives

  • President & Representative Director: Isao Teshirogi
  • Director & Executive Vice President: Takuko Sawada
  • Executive Officer: Takeshi Shiota
  • Executive Officer: Miyuki Hiura
  • Executive Officer & Personnel Manager: Noriyuki Kishida

Shareholders

  • Nomura Asset Management Co., Ltd. (6.8%)
  • Sumitomo Life Insurance Co. (5.9%)
  • Sumitomo Mitsui Banking Pension Fund (3.0%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • Nippon Life Insurance Co. (2.6%)
  • EdgePoint Investment Group, Inc. (2.5%)
  • The Vanguard Group, Inc. (2.5%)
  • Ping An Insurance (Group) Co. of China Ltd. (2.0%)
  • Capital International KK (1.5%)

Contact Details

Related Companies

  • Shionogi Pharma Co. Ltd.
  • Shionogi Healthcare Co. Ltd.
  • Shionogi & Co., Ltd. /2 Subsidiaries/
  • Shionogi & Co. Restricted Stock Compensation Plan
  • Shionogi Healthcare & Co. Ltd.
  • Pionnier KK
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi, Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co. Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • UMN Pharma, Inc.
  • Shionogi Bioresearch Corp.
  • Shionogi & Co. Ltd. Pension Fund
  • Daiwa Trading Co., Ltd.
  • Soei Co., Ltd.
  • Tetra Therapeutics Inc.
  • Tall Bridge, Inc.
  • C&O Pharmaceutical Technology (Holdings) Ltd.
  • QuatRx Pharmaceuticals Company
  • Shionogi Pharma, Inc.

Competitors

  • NanoViricides, Inc.
  • Vaxart, Inc.
  • aTyr Pharma, Inc.
  • Nabriva Therapeutics Plc
  • Spero Therapeutics, Inc.
  • TaiMed Biologics Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cocrystal Pharma Inc
  • CytoDyn Inc.
  • Iterum Therapeutics Plc
  • Achaogen, Inc.
  • Entasis Therapeutics Holdings, Inc.
  • Acura Pharmaceuticals, Inc.
  • VistaGen Therapeutics, Inc.
  • NEXT SCIENCE Co.,Ltd.
  • BELLUS Health Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Nektar Therapeutics
Last Updated on 25 Sep, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media